Patrick Neven

38.6k citations

493 papers · 15.7k indexed · 7 hit papers · h-index 57

Oncology top 0.1%
- HER2/EGFR in Cancer Research 93
- Cancer Treatment and Pharmacology 71
- Cancer Risks and Factors 40
Cancer Research top 0.1%
- Breast Cancer Treatment Studies 121
Obstetrics and Gynecology top 0.1%
- Endometrial and Cervical Cancer Treatments 40
Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment 38
Pulmonary and Respiratory Medicine top 0.2%
- Advanced Breast Cancer Therapies 144
Genetics
- Estrogen and related hormone effects 121

Co-authors: Ignace Vergote Frédéric Amant Philippe Moerman Erik Van Limbergen D. Timmerman Hans Wildiers Robert Paridaens Marie-Rose Christiaens
Cited by: Oncology Cancer Research Obstetrics and Gynecology
Journals: Cancer Research (61 papers)Journal of Clinical Oncology (60 papers)Annals of Oncology (45 papers)
Partner nations: Belgium United States France

In The Last Decade

Patrick Neven

468 papers receiving 15.4k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2021 Nature Medicine
2021 Annals of Oncology
2021 The Lancet Oncology
2019 JAMA Oncology
2017 Journal of Clinical Oncology
2014 Annals of Oncology
2005 The Lancet

Peers

Countries citing papers authored by Patrick Neven

Since Specialization

Citations

This map shows the geographic impact of Patrick Neven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Neven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Neven more than expected).

Fields of papers citing papers by Patrick Neven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Neven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Neven. The network helps show where Patrick Neven may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Patrick Neven, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick Neven Line = papers co-authored together Patrick Neven links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial ESMO Open ·Nadia Harbeck,Véronique Dièras,Karen A. Gelmon,Richard S. Finn,Miguel Martín,Patrick Neven,Seong‐Eun Kim,Jie Ma,Eric Gauthier,Zbigniew Mazur,Bao-Xuan Xie,Hope S. Rugo	2025	0
2	2MO Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial ESMO Open ·Abdul Latif Abdul Razak,Erika Hamilton,Yaroslav Kulyaba,敏昭天野,Patrick Neven,Wang Jiahe,Keya Yang,Claudio Zamagni,Vladimir I. Vladimirov,H. M. Saturnino,Carmela Ciardullo,信彦佐々木,Teresa Klinowska,Justin P.O. Lindemann,Robert McEwen,Christopher J. Morrow,Ekaterine Arkania	2024	2
3	Abstract PO3-05-05: The effect of histological breast cancer subtype on progression free survival in patients with CDK4/6 inhibitors Cancer Research ·Sohad Haj Yahya,Karen Van Baelen,Hans Wildiers,Giuseppe Floris,Sileny Han,Patrick Berteloot,Deyanira Garcia-Navas Núñez,Ann Smeets,Ines Nevelsteen,Yannick Van Herck,冯寿林,Ирина В. Ульянкина,理三好,Janic Mathias Istanto,Annouschka Laenen,Christine Desmedt,Patrick Neven	2024	0
4	Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292 Cancer Research ·Erika Hamilton,Patrick Neven,Barbara Pistilli,Muralidhar Beeram,Virginia F. Borges,Mario Campone,José Luiz Guimarães,Theodoros Foukakis,Annette Raskov Kodahl,Peter Lau,Elgene Lim,Iwona Ługowska,Hatice S Ercin,Christopher Gresty,Claire Miller,Roberto Sommavilla,Dhivya R. Sudhan,Hope S. Rugo	2024	2
5	196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2 ESMO Open ·Joyce O’Shaughnessy,冨岡寛美,Stephen Chia,Claudine Isaacs,Michelino De Laurentiis,Sherko Küemmel,Komal Jhaveri,Wolfgang Janni,Hope S. Rugo,Agnes Lteif,Safa M. Bani Mustafa,Howard Hu,Patrick Neven	2023	0
6	2MO Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC) ESMO Open ·T. Kh. Gazizov,基夫川端,Maxim De Schepper,Tatjana Geukens,Karen Van Baelen,Marion Maetens,Oliveira TR,Yitong Cao,Bram Boeckx,Andi Mas Jaya,Kevin Punie,Patrick Neven,Hans Wildiers,W. Van den Bogaert,Elia Biganzoli,Diether Lambrechts,Gianluca Floris,François Richard,Christine Desmedt	2023	1
7	273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2 Annals of Oncology ·Patrick Neven,Neil Stahl,María Vidal,M. Martín Jiménez,Peter A. Kaufman,Nadia Harbeck,Kelly K. Hunt,Oscar Eduardo Tovar,Taixuan Wan,PA Fasching,Philippe Aftimos,Duncan Wheatley,Erika Hamilton,Rebecca Aft,Swati Kulkarni,Roohi Ismail‐Khan,马德辉,Shawn T. Estrem,Umut Özbek,Eva Ciruelos	2023	4
8	LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes Annals of Oncology ·Nadia Harbeck,Priya Rastogi,J. O’Shaughnessy,Frances Boyle,Javier Cortés,Hope S. Rugo,Matthew P. Goetz,Erika Hamilton,Chiun‐Sheng Huang,Elżbieta Senkus,A. Tryakin,Patrick Neven,Jens Huober,Ran Wei,Valérie André,喻玫,Belén San Antonio,Ashwin Shahir,M. Martín Jiménez,Stephen Johnston	2023	11
9	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant Breast Cancer Research ·Patrick Neven,PA Fasching,Stephen Chia,Guy Jérusalem,Michelino De Laurentiis,Seock‐Ah Im,Katarína Petráková,Giulia Bianchi,V.I. Karelin,Arnd Nusch,Gabe S. Sonke,Luis de la Cruz‐Merino,J. Thaddeus Beck,Juan Pablo Zarate,Dai Arakawa,A. Chakravartty,Rogene F. Hederson,Dennis J. Slamon	2023	33
10	Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy Translational Oncology ·Sigrid Hatse,田島庸光,Christof Vulsteke,Kevin Punie,Patrick Neven,Ann Smeets,Annouschka Laenen,Hans Wildiers	2022	2
11	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer npj Breast Cancer ·Andrea Gombos,David Venet,Lieveke Ameye,Peter Vuylsteke,Patrick Neven,Vincent R. Richard,François P. Duhoux,Jean‐François Laes,Françoise Rothé,Christos Sotiriou,Marianne Paesmans,Ahmad Awada,Thomas Guiot,Patrick Flamen,Martine Piccart,Michail Ignatiadis,Géraldine Gebhart	2021	14
12	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach Clinical Pharmacology & Therapeutics ·名取早苗,YU Zhibin,Werner Schroth,Thomas E. Mürdter,Robin Michelet,Hiltrud Brauch,Wilhelm Huisinga,Markus Joerger,Patrick Neven,Stijn L.W. Koolen,Ron H.J. Mathijssen,Ellen Copson,Diana Eccles,Sylvia Chen,Balram Chowbay,Arafat Tfayli,Nathalie K. Zgheib,Matthias Schwab,Charlotte Kloft	2020	21
13	Effects of a mindfulness‐based intervention on cancer‐related cognitive impairment: Results of a randomized controlled functional magnetic resonance imaging pilot study Cancer ·Katleen Van der Gucht,Roger Duane Williams,William S. Morison,Anders Åstrand,Charlotte Sleurs,Ahmed Radwan,Jeroen Blommaert,Keisuke Takano,Mathieu Vandenbulcke,Hans Wildiers,Patrick Neven,Peter Kuppens,Filip Raes,Ann Smeets,Stefan Sunaert,Sabine Deprez	2020	44
14	Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cancer ·José Pablo Leone,Bernard F. Cole,Meredith M. Regan,Beat Thürlimann,Alan S. Coates,Manuela Rabaglio,Anita Giobbie‐Hurder,Richard D. Gelber,Bent Ejlertsen,Vernon Harvey,Patrick Neven,István Láng,Hervé Bonnefoi,Andrew Wardley,Aron Goldhirsch,Angelo Di Leo,Marco Colleoni,Inês Vaz-Luís,Nancy U. Lin	2020	5
15	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes Breast Cancer Research and Treatment ·Frederik Deman,Kevin Punie,Annouschka Laenen,Patrick Neven,Eva Oldenburger,Ann Smeets,Ines Nevelsteen,Chantal Van Ongeval,范卫平,F. Ariello,Melissa Christiaens,Hilde Janssen,Caroline Weltens,Christine Desmedt,Hans Wildiers,Giuseppe Floris	2020	9
16	Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab Acta Clinica Belgica ·MARY D. TESLER,Thomas Van Cann,Patrick Schöffski,Paul Clement,Oliver Bechter,Isabel Spriet,Ruxandra Coropciuc,Constantinus Politis,K.W.A. So,Joseph Schoenaers,Herlinde Dumez,Patrick Berteloot,Patrick Neven,Kristiaan Nackaerts,Feng Jung Sherida H. Woei-A-Jin,Kevin Punie,Hans Wildiers,Benoit Beuselinck	2017	40
17	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses Clinical Cancer Research ·Adriaan Vanderstichele,Pieter Busschaert,Dominiek Smeets,C. Landolfo,Els Van Nieuwenhuysen,Karin Leunen,Patrick Neven,Frédéric Amant,Sven� Mahner,Elena Ioana Braicu,Ana Carolina Brandão Veríssimo,An Coosemans,D. Timmerman,Diether Lambrechts,Ignace Vergote	2016	78
18	Chromosomal instability in cell-free DNA as a highly specific biomarker for ovarian cancer detection International Journal of Gynecological Cancer ·Adriaan Vanderstichele,Pieter Busschaert,Dominiek Smeets,Els Van Nieuwenhuysen,Karin Leunen,Patrick Neven,Frédéric Amant,Sven� Mahner,Elena Ioana Braicu,Robert Zeillinger,An Coosemans,D. Timmerman,Diether Lambrechts,Ignace Vergote	2016	2
19	Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium The Breast ·C WESTERKAMP,Adamczyk Ben,Marleen Praet,Guy Marchal,Annouschka Laenen,Marie-Rose Christiaens,Olivier Brouckaert,Afshin Halavati,Patrick Neven,Chantal Van Ongeval	2015	16
20	Relationship Between Age and Axillary Lymph Node Involvement in Women With Breast Cancer Journal of Clinical Oncology ·Hans Wildiers,Ben Van Calster,Lonneke V. van de Poll‐Franse,Wouter Hendrickx,Jo Røislien,Ann Smeets,Robert Paridaens,Karen Deraedt,Karin Leunen,Caroline Weltens,Sabine Van Huffel,Marie-Rose Christiaens,Patrick Neven	2009	58

About Patrick Neven

Patrick Neven is a scholar working on Oncology, Cancer Research and Obstetrics and Gynecology, having authored 493 papers that have together received 15.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (144 papers), Estrogen and related hormone effects (121 papers), Breast Cancer Treatment Studies (121 papers), HER2/EGFR in Cancer Research (93 papers), Cancer Treatment and Pharmacology (71 papers), Cancer Risks and Factors (40 papers), Endometrial and Cervical Cancer Treatments (40 papers) and Ovarian cancer diagnosis and treatment (38 papers). The work is most often cited by research in Oncology (8.6k citations), Cancer Research (4.5k citations) and Obstetrics and Gynecology (2.1k citations). Patrick Neven has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Ignace Vergote, Frédéric Amant, Philippe Moerman, Erik Van Limbergen, D. Timmerman, Hans Wildiers, Robert Paridaens, Marie-Rose Christiaens, Karin Leunen and Ann Smeets. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Breast Cancer Research and Treatment and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact